KBLBOTCPlastic Material, Synth Resin/Rubber, Cellulos (No Glass)Fiscal year ends December 31
Kraig Biocraft Laboratories, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.08−0.00 (-4.70%)
Close on Oct 19, 2026
- Market cap
- $90.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 144.4% | 83.1% | 44.9% | |
| Return on assets | -892.8% | -490.2% | -178.0% | |
| Current ratio | 0.12 | 0.11 | 0.18 | |
| Interest coverage | -21.1× | -827.6× | -5.9× | |
| Capex to revenue | 7.8% | – | – | |
| Diluted shares | 744M | 849M | 1.06B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kraig Biocraft Laboratories generated $8.56M from operations and spent $118.21K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$8.56M
Used
$118.21K
Capital expenditure$118.21K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-291.1%
×Asset turnover4.32×
×Equity multiplier-0.02×
=Return on equity, FY201829.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2018 | -291.1% | 4.32× | -0.02× | 29.8% |
| FY2017 | -2397.4% | 0.39× | -0.09× | 81.3% |
| FY2016 | -9648.6% | 0.09× | -0.16× | 144.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.62M
- Cash generatingOperating cash flow above zero-$1.79M
- Return on assets improvedROA up on the prior year-105.1% → -240.7%
- Earnings backed by cashOperating cash flow above net income-$1.79M vs -$3.62M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.08 → 0.18
- No dilutionShare count did not rise1.04B → 1.06B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –